Recruit or reboot? How does anti-PD-1 therapy change tumor-infiltrating lymphocytes? Editorial
| Authors: | Callahan, M. K.; Wolchok, J. D. |
| Title: | Recruit or reboot? How does anti-PD-1 therapy change tumor-infiltrating lymphocytes? |
| Abstract: | It has been widely assumed that PD-1 blockade works by reinvigorating (“rebooting”) pre-existing exhausted tumor-infiltrating ilymphocytes (TILs). A recent study challenges this paradigm, demonstrating that the majority of tumor-specific TILs after anti-PD-1 treatment have TCRs not identified in the tumor pre-therapy, suggesting they are newly recruited post-therapy. © 2019 Elsevier Inc. It has been widely assumed that PD-1 blockade works by reinvigorating (“rebooting”) pre-existing exhausted tumor-infiltrating ilymphocytes (TILs). A recent study challenges this paradigm, demonstrating that the majority of tumor-specific TILs after anti-PD-1 treatment have TCRs not identified in the tumor pre-therapy, suggesting they are newly recruited post-therapy. © 2019 Elsevier Inc. |
| Journal Title: | Cancer Cell |
| Volume: | 36 |
| Issue: | 3 |
| ISSN: | 1535-6108 |
| Publisher: | Cell Press |
| Date Published: | 2019-09-16 |
| Start Page: | 215 |
| End Page: | 217 |
| Language: | English |
| DOI: | 10.1016/j.ccell.2019.08.009 |
| PUBMED: | 31526757 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Short Survey -- Export Date: 1 October 2019 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work